Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells

BACKGROUND: Trastuzumab, a therapeutic monoclonal antibody directed against HER2, is routinely used to treat HER2-positive breast cancer with a good response rate. However, concerns have arisen in the clinical practice due to adverse side effects. One way to overcome these limitations is to encapsul...

Descripción completa

Detalles Bibliográficos
Autores principales: Caputo, Tania Mariastella, Barisciano, Giovannina, Mulè, Chiara, Cusano, Angela Maria, Aliberti, Anna, Muccillo, Livio, Colantuoni, Vittorio, Sabatino, Lina, Cusano, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683664/
https://www.ncbi.nlm.nih.gov/pubmed/38034948
http://dx.doi.org/10.2147/IJN.S429898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683664/
https://www.ncbi.nlm.nih.gov/pubmed/38034948
http://dx.doi.org/10.2147/IJN.S429898

Ejemplares similares